

**Company registration number: 267646**

**SUIR ENDOCRINE PRODUCTS LIMITED  
Trading as SUIR ENDOCRINE PRODUCTS LIMITED.**

**Unaudited abridged financial statements  
for the financial year ended 30 June 2025**

# SUIR ENDOCRINE PRODUCTS LIMITED

## Contents

	<b>Page</b>
Directors and other information	<b>1</b>
Directors responsibilities statement	<b>2</b>
Statement of changes in equity	<b>3</b>
Balance sheet	<b>4 - 5</b>
Notes to the abridged financial statements	<b>6 - 10</b>

## SUIR ENDOCRINE PRODUCTS LIMITED

### Directors and other information

<b>Directors</b>	Director Mr. D.F. Deasy Director Ms. C. M. Deasy
<b>Secretary</b>	Mr. D. F. Deasy
<b>Company number</b>	267646
<b>Registered office</b>	SUIR ENDOCRINE PRODUCTS LIMITED. Shaneeda, Ballinveiltig, Curaheen Road, Co. Cork.
<b>Business address</b>	Shaneeda, Ballinveiltig, Curraheen Road, Co. Cork.
<b>Accountants</b>	Patrick J. Kennedy & Co., Chartered Accountants, 6 William Street, Kilkenny
<b>Bankers</b>	Bank Of Ireland, Parnell Street, Clonmel, Co. Tipperary.
<b>Solicitors</b>	Donegans, Solicitors, No. 6 Lapps Quay, Cork.

## **SUIR ENDOCRINE PRODUCTS LIMITED**

### **Directors responsibilities statement**

These abridged financial statements have been extracted, pursuant to section 353 of the Companies Act 2014, from the statutory financial statements prepared under section 290 of that Act. The following is the Directors Responsibilities Statement accompanying those financial statements.

The directors are responsible for preparing the directors report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and Section 1A (small entities) FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and directors report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

On behalf of the board

Denis F. Deasy  
Director

Catherine M. Deasy  
Director

## SUIR ENDOCRINE PRODUCTS LIMITED

### Statement of changes in equity Financial year ended 30 June 2025

	Called up share capital €	Profit and loss account €	<b>Total</b>  €
<b>At 1 July 2023</b>	127	105,043	105,170
Profit for the financial year		5,052	5,052
<b>Total comprehensive income for the financial year</b>	-	5,052	5,052
<b>At 30 June 2024 and 1 July 2024</b>	127	110,095	110,222
Profit for the financial year		15,992	15,992
<b>Total comprehensive income for the financial year</b>	-	15,992	15,992
<b>At 30 June 2025</b>	127	126,087	126,214

**SUIR ENDOCRINE PRODUCTS LIMITED**

**Balance sheet  
As at 30 June 2025**

	Note	2025 €	€	2024 €	€
<b>Current assets</b>					
Stocks	8	4,010		4,052	
Debtors	9	3,801		231,630	
Cash at bank and in hand		138,201		79,258	
		<u>146,012</u>		<u>314,940</u>	
<b>Creditors: amounts falling due within one year</b>					
	10	<u>(19,798)</u>		<u>(204,718)</u>	
<b>Net current assets</b>		126,214		110,222	
<b>Total assets less current liabilities</b>		<u>126,214</u>		<u>110,222</u>	
<b>Creditors: amounts falling due after more than one year</b>					
		-		-	
<b>Net assets</b>		<u>126,214</u>		<u>110,222</u>	
<b>Capital and reserves</b>					
Called up share capital presented as equity		127		127	
Profit and loss account		126,087		110,095	
<b>Shareholders funds</b>		<u>126,214</u>		<u>110,222</u>	

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

**The notes on pages 6 to 10 form part of these abridged financial statements.**

## **SUIR ENDOCRINE PRODUCTS LIMITED**

### **Balance sheet (continued)**

**As at 30 June 2025**

We, as directors of SUIR ENDOCRINE PRODUCTS LIMITED state that:

- the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014;
- the company is availing itself of the exemption on the grounds that the conditions specified in section 358 of the Companies Act 2014 are satisfied;
- the shareholders of the company have not served a notice on the company under section 334(1) of the Companies Act 2014 in accordance with section 334(2);
- We acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the company; and
- the company has relied on the specified exemption contained in section 352 of the Companies Act 2014; has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 of the Companies Act 2014.

These abridged financial statements were approved by the board of directors on 4 February 2026 and signed on behalf of the board by:

Director Mr. D.F. Deasy  
Director

Director Ms. C. M. Deasy  
Director

**The notes on pages 6 to 10 form part of these abridged financial statements.**

## **SUIR ENDOCRINE PRODUCTS LIMITED**

### **Notes to the abridged financial statements Financial year ended 30 June 2025**

#### **1. General information**

The company is a private company limited by shares, registered in Ireland. The address of the registered office is SUIR ENDOCRINE PRODUCTS LIMITED., Shaneeda,, Ballinveiltig,, Curaheen Road,, Co. Cork..

#### **Statement Of Compliance**

The company qualifies as a small company as defined by Section 280A of the Act, in respect of the financial year and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Act and section 1A of FRS 102.

These financial statements present information about the company as an individual undertaking and not about its group. The company has availed of the exemption from the requirement to prepare group financial statements in section 297 of the Companies Act 2014.

#### **2. Accounting policies and measurement bases**

#### **3. Basis of preparation**

These financial statements have been prepared in compliance with FRS 102 Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and Irish statute comprising the Companies Act 2014.

The company qualifies as a small company as defined by Section 280A of the Act, in respect of the financial year and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Act and section 1A of FRS 102.

The financial statements are prepared in Euro (€) and all amounts have been rounded to the nearest euro.

#### **Turnover**

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer, usually on despatch of the goods; the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

## SUIR ENDOCRINE PRODUCTS LIMITED

### Notes to the abridged financial statements (continued) Financial year ended 30 June 2025

#### **Taxation**

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the profit and loss account, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively.

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

#### **Tangible assets**

Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.

#### **Depreciation**

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Fittings fixtures and equipment	- 12.5%%
Motor vehicles	- 12.5%

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

#### **Stocks**

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.

## SUIR ENDOCRINE PRODUCTS LIMITED

### Notes to the abridged financial statements (continued) Financial year ended 30 June 2025

#### Financial instruments

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

#### Ordinary Share Capital

The ordinary share capital of the company is presented as equity.

#### Cash and cash equivalents

Cash consists of cash on hand and demand deposits. Cash equivalents consist of short term highly liquid investments that are readily convertible to known amounts of cash that are subject to an insignificant risk of change in value.

#### Judgments

The directors consider the accounting assumptions below to be its critical accounting judgements:

#### Going Concern

The directors consider it appropriate to prepare the financial statements on a going concern basis as they have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future.

#### Stocks

Stocks are kept to a minimum and adequate allowance has been made to reflect the fact that its shelf life can be limited.

#### Foreign currencies

The Financial statements are expressed in Euro(€).

Transactions during the year have been translated at the rate of exchange ruling at the date of the transactions or at the related forward exchange contract rate where such contracts exist. Assets and liabilities denominated in foreign currencies are translated to Euro at the rates of exchange ruling at the Balance Sheet date or at the related forward exchange contract rate where such contracts exist. The resulting profits or losses are dealt with in the profit and loss account.

#### 4. Staff numbers

The average number of persons employed by the company during the financial year, including the directors was 1 (2024: 1).

#### 5. Profit before tax

Profit is stated after charging/(crediting):

	2025	2024
	€	€
Depreciation of tangible assets	-	511

**SUIR ENDOCRINE PRODUCTS LIMITED**

**Notes to the abridged financial statements (continued)  
Financial year ended 30 June 2025**

**6. Tax on profit**

**Major components of tax expense**

	<b>2025</b>	<b>2024</b>
	€	€
<b>Current tax:</b>		
Irish current tax expense	2,292	558
<b>Tax on profit</b>	<u>2,292</u>	<u>558</u>

**7. Tangible assets**

	Plant and machinery	Fixtures, fittings and equipment	<b>Total</b>
	€	€	€
<b>Cost</b>			
At 1 July 2024 and 30 June 2025	<u>1,674</u>	<u>85,307</u>	<u>86,981</u>
<b>Depreciation</b>			
At 1 July 2024 and 30 June 2025	<u>1,674</u>	<u>85,307</u>	<u>86,981</u>
<b>Carrying amount</b>			
At 30 June 2025	<u>-</u>	<u>-</u>	<u>-</u>
At 30 June 2024	<u>-</u>	<u>-</u>	<u>-</u>

**8. Stocks**

	<b>2025</b>	<b>2024</b>
	€	€
Finished goods and goods for resale	<u>4,010</u>	<u>4,052</u>

The replacement cost of stock did not, in the directors' opinion, differ significantly from the figures shown.

**9. Debtors**

	<b>2025</b>	<b>2024</b>
	€	€
Trade debtors	2	225,909
VAT	3,799	5,721
	<u>3,801</u>	<u>231,630</u>

## SUIR ENDOCRINE PRODUCTS LIMITED

### Notes to the abridged financial statements (continued) Financial year ended 30 June 2025

#### 10. Creditors: amounts falling due within one year

	2025	2024
	€	€
PAYE	3,175	3,298
Corporation tax	1,525	222
	<u>4,700</u>	<u>3,520</u>

Amounts owed to group entities are repayable on demand, unsecured and interest free.

#### 11. Events after the end of the reporting period

There were no significant events between the Balance Sheet date and the date of signing of the financial statements, which require adjustment to or disclosure in the financial statements.

#### 12. Related party transactions

The company purchased professional services from Barry Deasy Consulting Limited, parent undertaking, amounting to €Nil (2024 : €16,585) during the year.

The company sold goods to Barka Limited , a group company, amounting to €Nil (2024:€Nil) during the year. The company sold professional services to Barka Limited, a group company, amounting to €Nil (2024 : €nil) during the year.

At the year end an amount of €nil (2024:€nil) is owed to the companies parent Barry Deasy Consulting Limited and an amount of €1,230 (2024 : €1,230) is owed to a group company Barka Limited.

Key management personnel

All directors and ceertain senior employeeswho have authority and responsibility for planning, directing and controlling the activities of the company are considered to be key management personnel. Total remuneration in respect of these individuals is €Nil.

#### 13. Parent Undertaking And Controlling Party

The company is a subsidiary of Barry Deasy Consulting Limited, a company incorporated in Ireland. The registered office of Barry Deasy Consulting Limited is Shaneeda, Curaheen Road, Ballinveiltig, Co. Cork.

Barry Deasy, director, holds 100% of the ordinary share capital of Barry deasy Consulting Limited and is deemed to be the ultimate controlling party.

#### 14. Approval of financial statements

The board of directors approved these abridged financial statements for issue on 4 February 2026.